Clinical Trial Search

Primary: Change From Baseline in Blood Pressure, as Measured by an Automated Oscillometric Blood Pressure Device. — -3.00; -6.67; -6.00; -7.67 mmHg

Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg

Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour

Primary: Change in Urinary Sodium Excretion (UNaV) — 11.8; 15.2 pg/ml

Primary: Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI) — -0.202; 0.430; -1.745; -0.407 mmol/L

Primary: Comparative Performance of Clinic, Home, and Kiosk — -4.7; -0.1; 9.5; -7.2 millimeters of mercury — p=<0.05

Primary: Muscle Sympathetic Nerve Activity at Rest — 41; 43.8 bursts/minute

Primary: Change in Mean Systolic Blood Pressure (SBP) — -10.58; -4.65 mmHg — p=<0.0001

Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg

Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants

Primary: Strokes, Either Fatal or Nonfatal — 24; 7 participants — p=0.19

Primary: SBP — 130.2; 128.8 mm Hg

Primary: Aortic Systolic Blood Pressure (SBP) — 112.7; 107.7; 106.2; 106.6 mm Hg

Primary: Change Ambulatory Systolic Blood Pressure — -29.3 mmHg

Primary: Blood Pressure — -10.1; -9.1 mm Hg — p=0.50

Primary: Performance of Blood Pressure Referral Threshold — .841 proportion

Primary: Systolic Blood Pressure — 138.35; 135.56 mmHg — p=0.0050

Primary: Mean Systolic Blood Pressure (SBP) Difference at 6 Months Post-intervention Compared to Usual Care. — -9.2; -14.0 mmHg

Primary: The Number of Patients for Whom Each Drug is Selected as the Preferred Therapy — 16; 8; 4 Participants

Primary: Unadjusted and Adjusted Changes From Baseline in Systolic and Diastolic Blood Pressure at Weeks 1, 3, 6 — -1.2; -5.3; 0.8; -1.7 mmHg

Primary: Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)). — -12.06; -13.33 mmHg

Primary: Percentage of Patient Visits With Completion of Out-of-office BP Monitoring Within 6 Months of an Eligible Visit During the Pre-Implementation Period — 0.6; 5.4…

Primary: Change in Oral Glucose Tolerance Test (OGTT) Area Under Curve (AUC) After Addition of Trandolapril to Hydrochlorothiazide (HCTZ) Compared With Change in OGTT AUC After…

Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2

Primary: Change in Blood Pressure From Baseline to Treatment — -7.56; -7.97; -7.68; -11.70 mmHg — p=<0.0001

Primary: Change of Systolic Ambulatory Blood Pressure From Baseline to 12 Weeks — -10.5 mmHg — p=0.01

Primary: Cardiac Output — 3.9; 4.10; 4.6 L/min

Primary: Percent of Patients Taking Thiazide Diuretics and at BP Goal at Index Visit and 6 Months — 35; 33; 43; 19 Participants

Primary: Blood Pressure — 103; 106; 94; 101 mmHg

Primary: Number of Participants Who Died Within 7 Days After Discharge From the Emergency Department — 0; 0 participants